Author:
Yu Qian,Wang Yating,Ungchusri Ethan,Patel Mikin,Kumari Divya,Van Ha Thuong,Pillai Anjana,Liao Chih-yi,Ahmed Osman
Reference18 articles.
1. Understanding the tumor immune microenvironment (TIME) for effective therapy;Binnewies;Nat Med,2018
2. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial;Finn;J Clin Oncol,2020
3. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial;Yau;Lancet Oncol,2022
4. Innate and adaptive immune cells in the tumor microenvironment;Gajewski;Nat Immunol,2013
5. Safety of combining radiotherapy with immune-checkpoint inhibition;Hwang;Nat Rev Clin Oncol,2018
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献